Clinical Trials

NCT04876781 | RECRUITING
200 participants

Korean Post-marketing Surveillance for Xeljanz XR

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-03
Start Date:
2022-01-12
Completion:
2026-09-22
Conditions
  • Active Moderate to Severe Rheumatoid Arthritis
  • Active Ankylosing Spondylitis
  • Active Psoriatic Arthritis
Interventions
  • DRUG
No Results Yet
NCT04753970 | RECRUITING | PHASE1/PHASE2
100 participants

Retina is a Marker for Cerebrovascular Heath

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-03
Start Date:
2021-02-09
Completion:
2030-06-30
Conditions
  • Cerebral Small Vessel Diseases
  • Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
  • Cerebral Microbleeding
  • Sporadic White Matter Disease
Interventions
  • DRUG
No Results Yet
NCT04512287 | COMPLETED | PHASE2
65 participants

PRP for Treatment of Peyronie's Disease

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-03
Start Date:
2021-03-29
Completion:
2025-08-11
Conditions
  • Peyronie Disease
  • Sexual Dysfunction, Physiological
  • Sexual Dysfunction Male
  • Genital Diseases, Male
Interventions
  • BIOLOGICAL
  • OTHER
No Results Yet
NCT04320888 | ACTIVE_NOT_RECRUITING | PHASE2
1 participants

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-03
Start Date:
2021-05-03
Completion:
2024-09-30
Conditions
  • Hematopoietic and Lymphatic System Neoplasm
  • Recurrent Ependymoma
  • Recurrent Ewing Sarcoma
  • Recurrent Hepatoblastoma
  • Recurrent Histiocytic and Dendritic Cell Neoplasm
  • Recurrent Langerhans Cell Histiocytosis
  • Recurrent Lymphoma
  • Recurrent Malignant Germ Cell Tumor
  • Recurrent Malignant Glioma
  • Recurrent Malignant Solid Neoplasm
  • Recurrent Medulloblastoma
  • Recurrent Neuroblastoma
  • Recurrent Non-Hodgkin Lymphoma
  • Recurrent Osteosarcoma
  • Recurrent Peripheral Primitive Neuroectodermal Tumor
  • Recurrent Rhabdoid Tumor
  • Recurrent Rhabdomyosarcoma
  • Recurrent Soft Tissue Sarcoma
  • Recurrent WHO Grade 2 Glioma
  • Refractory Ependymoma
  • Refractory Ewing Sarcoma
  • Refractory Hepatoblastoma
  • Refractory Histiocytic and Dendritic Cell Neoplasm
  • Refractory Langerhans Cell Histiocytosis
  • Refractory Lymphoma
  • Refractory Malignant Germ Cell Tumor
  • Refractory Malignant Glioma
  • Refractory Malignant Solid Neoplasm
  • Refractory Medulloblastoma
  • Refractory Neuroblastoma
  • Refractory Non-Hodgkin Lymphoma
  • Refractory Osteosarcoma
  • Refractory Peripheral Primitive Neuroectodermal Tumor
  • Refractory Rhabdoid Tumor
  • Refractory Rhabdomyosarcoma
  • Refractory Soft Tissue Sarcoma
  • Refractory WHO Grade 2 Glioma
  • Wilms Tumor
Interventions
  • PROCEDURE
  • DRUG
NCT04284787 | ACTIVE_NOT_RECRUITING | PHASE2
60 participants

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-03
Start Date:
2021-02-16
Completion:
2023-06-05
Conditions
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
  • Acute Myeloid Leukemia Post Cytotoxic Therapy
  • Secondary Acute Myeloid Leukemia
Interventions
  • DRUG
  • PROCEDURE
  • BIOLOGICAL
Previous
Sorted by latest updates
Next
Showing 40 trials per page